ESTIMATION OF THE PREVALENCE OF NON-ALCOHOLIC FATTY LIVER DISEASE IN THE FORM OF LIVER FIBROSIS IN PATIENTS WITH CHRONIC PANCREATITIS USING THE NAFLD FIBROSIS SCORE INDEX
Introduction: Non-alcoholic fatty liver disease (NAFLD), which develops against the background of type 2 diabetes mellitus, obesity and arterial hypertension, has become one of the most common chronic metabolic diseases in recent years. The presence of fatty liver or NAFLD in pancreatitis occurs with a prevalence of 18 to 43%, which in turn aggravated the course of pancreatitis.
Aim: To study the prevalence of non-alcoholic fatty liver disease in the form of liver fibrosis using the NAFLD Fibrosis Score.
Materials and methods: Study design - a single-stage retrospective cross-sectional study. Inclusion criteria: males and females aged 18 to 75 years with a confirmed diagnosis of non-alcoholic fatty liver disease in patients who received inpatient treatment at the Gastroenterology Department of the University Hospital of NJSC "Semey Medical University" in the period 01.01.2021 to 12.31.2022. Exclusion criteria: presence malignant neoplasms; pregnancy, lactation. Liver fibrosis was assessed by the NAFLD Fibrosis Score.
Results: When studying the average values of the NAFLD Fibrosis Score by sex, BMI, a statistically significant difference was revealed. When studying the distribution of risk factors according to the degree of liver fibrosis, an associative relationship was found with BMI (p=0.001). The chance of developing liver fibrosis, regardless of the degree of fibrosis, increased in patients with overweight and obesity by 2.94 times (95% CI: 1.67-5.3) (p=0.001) compared with those who had normal BMI. The ROC-analysis with the construction of ROC-curves revealed the relationship between the prognosis of the degree of liver fibrosis and BMI indices p=0.0001. With an equal BMI or higher, a high risk of developing liver fibrosis was predicted. The sensitivity and specificity of the method were 95% and 76.9%, respectively. Also, correlations were found between the prognosis of the degree of liver fibrosis and age, p=0.0001. At an equal or greater age, a high risk of developing liver fibrosis was predicted. The sensitivity and specificity of the method were 98.8% and 79.3%, respectively.
Conclusions: Thus, the use of the NAFLD Fibrosis Score in practice will allow timely and inexpensive detection of the presence of liver fibrosis after the age of 35 years and with a BMI above 22.76.
Aizhan Т. Shakhanova1, http://orcid.org/0000-0001-8214-8575
Zauresh K. Zhumadilova1, https://orcid.org/0000-0001-6211-6154
Alida Sh. Kaskabaeva1, http://orcid.org/0000-0002-5184-214X
Tungyshkhan E. Shakhanov1, http://orcid.org/0000-0002-8698-7541
Karlygysh Sh. Zhylkybayeva2, Daulet K. Muzdubaev1
1 NJSC «Semey medical university», Semey, Republic of Kazakhstan;
2 University Hospital of NJSC "Semey Medical University", Semey, Republic of Kazakhstan.
1. Гржибовский А.М. Типы данных, проверка распределения и описателная статистика // Экология человека. 2008. 01. С. 52–58.
2. Есина М.В. Распространенность неалкоголной жировой болезни печени среди патциентов с сердечно-сосудистыми заболеваниями // Материалы XXII научно-практической конференции молодых ученых, аспирантов и студентов Национального исследовательского Мордовского Государственного университета им. Н.П. Огарева. 2019. С. 294–297.
3. Раимкулова Н.Р., Мамадалиева Н. И., Обидова Д.Д. Распространенность неалкоголной жировой болезни печени и желчекаменной болезни // International Journal of Discourse on Innovation, Integration and Education. 2020. № 5 (1). С. 58–60.
4. Araújo A.R. Global epidemiology of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: What we need in the future // Liver International. 2018. № November 2017 (38). Р. 47–51.
5. Bonacini M. Racial differences in prevalence and severity of non-alcoholic fatty liver disease // World Journal of Hepatology. 2021. № 7 (13). Р. 763–773.
6. Feng R.N. Lean-non-alcoholic fatty liver disease increases risk for metabolic disorders in a normal weight Chinese population. // World journal of gastroenterology. 2014. № 47 (20). Р. 17932–40.
7. Hou S. Fatty liver disease is associated with the severity of acute pancreatitis:A systematic review and meta-analysis. // International journal of surgery (London, England). 2019. (65). Р. 147–153.
8. Kabir M.A. Prevalence of Non-Alcoholic Fatty Liver Disease and Its Biochemical Predictors in Patients with Type-2 Diabetes Mellitus. // Mymensingh medical journal : MMJ. 2018. № 2 (27). Р. 237–244.
9. Khneizer G., Rizvi S., Gawrieh S. Non-alcoholic Fatty Liver Disease and Diabetes Mellitus. // Advances in experimental medicine and biology. 2021. (1307). Р. 417–440.
10. Kumar R. Clinicopathological characteristics and metabolic profiles of non-alcoholic fatty liver disease in Indian patients with normal body mass index: Do they differ from obese or overweight non-alcoholic fatty liver disease? // Indian journal of endocrinology and metabolism. 2013. № 4 (17). Р. 665–71.
11. Lee W.G. Prevalence of diabetes in liver cirrhosis: A systematic review and meta-analysis. // Diabetes/metabolism research and reviews. 2019. № 6 (35). Р. e3157.
12. Mach F. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk // European Heart Journal. 2020. № 1 (41). Р. 111–188.
13. McPherson S. Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis. // The American journal of gastroenterology. 2017. № 5 (112). Р. 740–751.
14. Mishina E.E. Nonalcoholic fatty liver disease: cause or consequence of insulin resistance? // Diabetes mellitus. 2017. № 5 (20). Р. 335–343.
15. Palgova L.K. Epidemiological features of non-alcoholic fatty liver disease in the North-West region of Russia (Results of an open multicenter prospective study DIREG 2) // Vestnik of Saint Petersburg University. Medicine. 2017. № 2 (12). Р. 118–135.
16. Petrov M.S. Editorial: abdominal fat: a key player in metabolic acute pancreatitis. // The American journal of gastroenterology. 2013. № 1 (108). Р. 140–2.
17. Schwabe R.F., Tabas I., Pajvani U.B. Mechanisms of Fibrosis Development in Nonalcoholic Steatohepatitis. // Gastroenterology. 2020. № 7 (158). Р. 1913–1928.
18. Shin K.Y. Influence of obesity on the severity and clinical outcome of acute pancreatitis. // Gut and liver. 2011. № 3 (5). Р. 335–9.
19. Wu D. Nonalcoholic Fatty Liver Disease Aggravated the Severity of Acute Pancreatitis in Patients. // BioMed research international. 2019. (2019). Р. 9583790.
20 Xiao A.Y. Global incidence and mortality of pancreatic diseases: a systematic review, meta-analysis, and meta-regression of population-based cohort studies. // The lancet. Gastroenterology & hepatology. 2016. № 1 (1). Р. 45–55.
21. Younossi Z.M. Nonalcoholic fatty liver disease in lean individuals in the United States. // Medicine. 2012. № 6 (91). 319–327.
References: [1-3]
1. Grzhibovskii A.M. Tipy dannykh, proverka raspredeleniya i opisatelnaya statistika [Data types, control of distribution and descriptive statistics]. Ekologiya cheloveka [Human Ecology]. 2008. 1. pp. 52–58. [in Russian]
2. Esina M.V. Rasprostranennost nealkogolnoi zhirovoi bolezni pecheni sredi patsientov s serdechno-sosudistymi zabolevaniyami [Prevalence of non-alcoholic fatty liver disease among patients with cardiovascular diseases]. Materialy XXII nauchno-prakticheskoi konferentsii molodykh uchenykh, aspirantov i studentov Natsionalnogo issledovatelskogo Mordovskogo gosudarstvennogo universiteta im. N.P. Ogareva. 2019. pp. 294–297. [in Russian]
3. Raimkulova N.R., Mamadalieva N. I., Obidova D. D. Rasprostranennost nealkogolnoi zhirovoi bolezni pecheni i zhelchekamennoi bolezni [Prevalence of non-alcoholic fatty liver disease and cholelithiasis]. International Journal of Discourse on Innovation, Integration and Education. 2020. № 5 (1). pp. 58–60. [in Russian]
Number of Views: 67
Category of articles:
Original articles
Bibliography link
Shakhanova A.T., Zhumadilova Z.K., Kaskabaeva A.Sh., Shakhanov T.E., Zhylkybaeva K.Sh., Muzdubaev D.K. Estimation of the prevalence of non-alcoholic fatty liver disease in the form of liver fibrosis in patients with chronic pancreatitis using the NAFLD Fibrosis Score index // Nauka i Zdravookhranenie [Science & Healthcare]. 2023, (Vol.25) 1, pp. 67-73. doi 10.34689/SH.2023.25.1.008Related publications:
ANALYSIS OF CLINICAL AND DEMOGRAPHIC INDICATORS OF PATIENTS WITH PARKINSON'S DISEASE IN THE SOUTHERN REGION OF KAZAKHSTAN
A COMPARATIVE STUDY OF DRUG POLICY REGARDING ORPHAN DISEASES IN THE USA, THE EUROPEAN UNION, AND THE REPUBLIC OF KAZAKHSTAN
MUTATIONS IN CARDIAC ION CHANNEL GENES IN KAZAKHSTANI PATIENTS WITH LONG QT SYNDROME
GENETIC FEATURES OF CONGENITAL DYSFUNCTION OF THE ADRENAL CORTEX CAUSED BY 21-HYDROXYLASE DEFICIENCY IN PERSONS OF KAZAKH NATIONALITY
NON-MOTOR SYMPTOMS IN PARKINSON'S DISEASE USING THE EXAMPLE OF AKTOBE PATIENTS